NCT04470648 is a clinical trial of blood test for SARS-COV2 serology in SARS-COV2 Infection, sponsored by Institut National de la Santé Et de la Recherche Médicale, France.

Who is sponsoring NCT04470648?

NCT04470648 is sponsored by Institut National de la Santé Et de la Recherche Médicale, France.

What drugs are being tested in NCT04470648?

Interventions in NCT04470648: blood test for SARS-COV2 serology.

What condition does NCT04470648 study?

NCT04470648 studies SARS-COV2 Infection.

Is NCT04470648 still recruiting?

NCT04470648 is currently completed. Last updated 26 January 2026.

Last reviewed 2026-01-26 · How we verify

NCT04470648

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

COVID-19 Infection at Samusocial in Paris: Descriptive and Serological Survey

Completed Last updated 26 January 2026

What this trial tests

trial testing blood test for SARS-COV2 serology in SARS-COV2 Infection in 179 participants. Completed in 22 August 2021.

Timeline

22 July 2020

Primary endpoint
8 April 2021

22 August 2021

Quick facts

Lead sponsor	Institut National de la Santé Et de la Recherche Médicale, France
Status	Completed
Study type	OBSERVATIONAL
Enrollment	179
Start date	22 July 2020
Primary completion	8 April 2021
Estimated completion	22 August 2021
Sites	3 locations across France

Drugs / interventions tested

blood test for SARS-COV2 serology

Conditions studied

SARS-COV2 Infection — all drugs for SARS-COV2 Infection →

Sponsor

Institut National de la Santé Et de la Recherche Médicale, France — full company profile →

Who can join

18 and older, any sex, with SARS-COV2 Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Study of COVID-19 seroprevalence in precarious population living in shelters of Samusocial de Paris and in staff working in these centers during COVID-19 epidemic.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Impact of the COVID-19 pandemic on the homeless: results from a retrospective closed cohort in France (March-May 2020).
Husain M, Rachline A, Cousien A, Rolland S, et al · · 2021 · cited 11× · PMID 34111590 · DOI 10.1016/j.cmi.2021.05.039

Verify or expand the search:

Other Institut National de la Santé Et de la Recherche Médicale, France trials

Trials by the same sponsor.

NCT07311213 — GENES AND AUTISM - IPSC · NA · not yet recruiting
NCT07063719 — Identification of Cellular Biomarkers of Rare Eye Diseases in Adults · NA · not yet recruiting
NCT06906042 — Multimodal Cardiovascular and Hepatic Population Imaging · recruiting
NCT06951035 — Impact of rTMS on BCI Control in Upper Limb Motor Rehabilitation of Patients With Chronic Stroke · NA · not yet recruiting
NCT06660108 — MOLECULAR BASIS OF LANGUAGE DEVELOPMENT AND ASSOCIATED DISORDERS · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04470648 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institut National de la Santé Et de la Recherche Médicale, France
Last refreshed: 26 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04470648.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing